Compare Novavax Inc (NVAX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.

Virgin Galactic (SPCE) trades at $2.94, down 2.33% with a bearish technical signal. The company continues to report significant losses with negative gross and net income margins, though recent quarters have shown smaller-than-expected losses. Cash flow remains negative despite improving trends, with management targeting positive quarterly cash flow by 2027. Analyst sentiment is divided with a slight lean toward Hold.

The outlook remains speculative with high execution risk. While space tourism offers long-term potential, ongoing losses, debt burden, and delayed commercial flights create substantial headwinds. The stock presents a high-risk opportunity for investors betting on successful commercialization, but requires careful risk management given the company's financial challenges.